Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kairos Pharma, Ltd. ( (KAPA) ) has issued an announcement.
On October 8, 2025, Kairos Pharma, Ltd.‘s Compensation Committee approved the grant of $950,000 in restricted stock units (RSUs) under its 2023 Equity Incentive Plan to certain executive officers and directors for their service from October 2025 to October 2026. The RSUs, calculated at a per share price of $1.31, will vest fully on October 8, 2026, and are subject to continuous service or immediate vesting upon a change in control. Additionally, cash bonuses totaling $227,500 were awarded for fiscal year 2024 performance, with key executives receiving varying amounts. This move aims to recognize and incentivize the company’s leadership, potentially impacting its operational focus and stakeholder confidence.
The most recent analyst rating on (KAPA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Average Trading Volume: 1,344,393
Technical Sentiment Signal: Buy
Current Market Cap: $25.1M
For a thorough assessment of KAPA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “More Hopeful than Real”: Is a Bidding War Brewing for Warner Bros. Discovery Stock (NASDAQ:WBD)?
- “Didn’t Develop the Way Automakers Thought.” Ford Notches Up, Reconsidering the EV Market
- “Our Focus is Increasingly…on Inference”: Intel Stock (NASDAQ:INTC) Jumps With Crescent Island Testing Next Year